Crispr Therapeutics vs Viking Therapeutics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Crispr Therapeutics AG (CRSP)

Q3 202618 Jun – 24 Sep 2026

▲3▼1

CRISPR Q3: Casgevy pediatric approval, revenue jump, pipeline catalysts

Casgevy FDA approval for young children Casgevy won FDA approval for children as young as two, expanding the eligible U.S. patient pool by about 5,500 and opening a potential $12.1 billion market. This directly boosts future revenue prospects.
This is a major new approval that expands the market and is a key positive driver for the stock.
Q2 revenue surge and strong cash position Q2 revenue jumped 78% sequentially to $76 million, net loss narrowed, and $2.36 billion in cash funds years of operations. This shows improving financial health and reduces near-term funding risk.
Financial results are a key driver of investor sentiment and stock price.
Pipeline catalysts and competitive win Upcoming data for CTX310 (cholesterol) and CTX611 (clot therapy), plus off-the-shelf CAR-T, could drive value. Novartis's pelacarsen failure may boost CRSP's CTX321, and Ken Fisher opened a small stake.
Pipeline progress and competitive dynamics are important for future growth prospects.
Adoption challenges and valuation uncertainty Casgevy adoption is slow due to complex procedures, revenue is still tiny against continuing losses, CTX321's advantage is only animal-tested, and valuation is highly assumption-dependent. Analyst targets average $86.21, below one model's $221.98 fair value.
These risks could limit upside and are important counterweights to the positive drivers.

August 202612 Jul – 24 Sep 2026

▲3

Casgevy sales jump, FDA widens label, and a rival's failure lifts CRSP's pipeline hopes

Casgevy revenue accelerates and FDA widens the label Q2 Casgevy revenue hit $76 million, up 78% from the prior quarter and 151% from a year ago, and the FDA approved it for children as young as 2, adding roughly 5,500 eligible patients. Net loss narrowed to $91.2 million from $208.5 million, with $2.36 billion in cash. Real sales and a bigger market make the gene-editing story less speculative, supporting the stock.
This is the clearest new fundamental proof that CRSP's only approved product is selling and its market is expanding.
Novartis heart-drug failure may push CRSP's next-gen program forward Novartis's pelacarsen failed its Phase 3 heart trial despite lowering Lp(a), a rival approach. Citi says this makes CRSP more likely to prioritize its more potent next-generation CTX321 Lp(a) candidate, and kept a Buy rating and $88 target. Less competition and a clearer pipeline focus help the stock, though CTX321's advantage is only shown in animals so far.
A competitor's failure directly changes CRSP's pipeline priorities and analyst view, a new force on the stock.
Ken Fisher's fund discloses a new CRSP stake Billionaire Ken Fisher's Fisher Asset Management opened a new position of 77,960 CRISPR Therapeutics shares worth about $4.25 million as of June 30, per 13F filings. A well-known investor buying in can draw attention and fresh demand to a beaten-down stock, though the position is small relative to CRSP's size.
A new institutional buyer is a fresh, concrete signal of outside money coming into the stock.
Valuation debate: cheap on cash-flow models, fair on book value One model pegs fair value at $221.98, implying the stock is deeply undervalued, while analyst targets average $86.21 and price-to-book sits near the industry average. CRSP still loses money on tiny revenue, so whether it is cheap depends entirely on assumptions about future Casgevy and pipeline sales. That uncertainty cuts both ways.
It frames the central bull-bear tension behind the stock's price without repeating any single event.

Latest12 Jul – 24 Sep 2026

▲3

Casgevy sales jump, FDA widens label, and a rival's failure lifts CRSP's pipeline hopes

Casgevy revenue accelerates and FDA widens the label Q2 Casgevy revenue hit $76 million, up 78% from the prior quarter and 151% from a year ago, and the FDA approved it for children as young as 2, adding roughly 5,500 eligible patients. Net loss narrowed to $91.2 million from $208.5 million, with $2.36 billion in cash. Real sales and a bigger market make the gene-editing story less speculative, supporting the stock.
This is the clearest new fundamental proof that CRSP's only approved product is selling and its market is expanding.
Novartis heart-drug failure may push CRSP's next-gen program forward Novartis's pelacarsen failed its Phase 3 heart trial despite lowering Lp(a), a rival approach. Citi says this makes CRSP more likely to prioritize its more potent next-generation CTX321 Lp(a) candidate, and kept a Buy rating and $88 target. Less competition and a clearer pipeline focus help the stock, though CTX321's advantage is only shown in animals so far.
A competitor's failure directly changes CRSP's pipeline priorities and analyst view, a new force on the stock.
Ken Fisher's fund discloses a new CRSP stake Billionaire Ken Fisher's Fisher Asset Management opened a new position of 77,960 CRISPR Therapeutics shares worth about $4.25 million as of June 30, per 13F filings. A well-known investor buying in can draw attention and fresh demand to a beaten-down stock, though the position is small relative to CRSP's size.
A new institutional buyer is a fresh, concrete signal of outside money coming into the stock.
Valuation debate: cheap on cash-flow models, fair on book value One model pegs fair value at $221.98, implying the stock is deeply undervalued, while analyst targets average $86.21 and price-to-book sits near the industry average. CRSP still loses money on tiny revenue, so whether it is cheap depends entirely on assumptions about future Casgevy and pipeline sales. That uncertainty cuts both ways.
It frames the central bull-bear tension behind the stock's price without repeating any single event.

July 202618 Jun – 22 Jul 2026

▲3

Casgevy label expansion and pipeline catalysts drive CRISPR's long-term story

Casgevy approved for toddlers, adding billions in market The FDA expanded Casgevy's approval to children as young as two, adding about 5,500 U.S. patients and a potential $12.1 billion opportunity at $2.2 million per treatment. CRISPR shares 60:40 profits with Vertex, so this directly grows future revenue.
This is the biggest concrete new event that expands the commercial market for CRISPR's only approved drug.
New DNA-shredding CRISPR tool could widen the field Scientists unveiled a CRISPR-based tool that kills diseased cells by shredding their DNA, potentially treating cancers that affect 40-50% of patients. CRISPR Therapeutics doesn't own it, but its existing delivery infrastructure could give it an edge if the field grows.
It shows the gene-editing market expanding, which supports the long-term investment case for CRISPR.
Pipeline catalysts: cholesterol drug, clot therapy, CAR-T Analysts point to upcoming CTX310 cholesterol trial results, a new partnership for clot-prevention therapy CTX611, and an off-the-shelf CAR-T cancer program as future growth drivers. Cathie Wood's Ark holds $362 million in CRSP, betting on these catalysts.
These pipeline programs are the main reasons investors expect CRISPR to grow beyond Casgevy.
Slow Casgevy sales and losses offset by $2.4B cash CRISPR reported only $1.46 million in quarterly revenue and a $122.9 million net loss, as Casgevy adoption stays slow due to complex treatment procedures. Still, $2.4 billion in cash gives it years of funding, and treatment centers are increasing.
This is the main counterweight: the company is still far from profitable, which limits near-term upside.

18 Jun – 22 Jul 2026

▲3

Casgevy label expansion and pipeline catalysts drive CRISPR's long-term story

Casgevy approved for toddlers, adding billions in market The FDA expanded Casgevy's approval to children as young as two, adding about 5,500 U.S. patients and a potential $12.1 billion opportunity at $2.2 million per treatment. CRISPR shares 60:40 profits with Vertex, so this directly grows future revenue.
This is the biggest concrete new event that expands the commercial market for CRISPR's only approved drug.
New DNA-shredding CRISPR tool could widen the field Scientists unveiled a CRISPR-based tool that kills diseased cells by shredding their DNA, potentially treating cancers that affect 40-50% of patients. CRISPR Therapeutics doesn't own it, but its existing delivery infrastructure could give it an edge if the field grows.
It shows the gene-editing market expanding, which supports the long-term investment case for CRISPR.
Pipeline catalysts: cholesterol drug, clot therapy, CAR-T Analysts point to upcoming CTX310 cholesterol trial results, a new partnership for clot-prevention therapy CTX611, and an off-the-shelf CAR-T cancer program as future growth drivers. Cathie Wood's Ark holds $362 million in CRSP, betting on these catalysts.
These pipeline programs are the main reasons investors expect CRISPR to grow beyond Casgevy.
Slow Casgevy sales and losses offset by $2.4B cash CRISPR reported only $1.46 million in quarterly revenue and a $122.9 million net loss, as Casgevy adoption stays slow due to complex treatment procedures. Still, $2.4 billion in cash gives it years of funding, and treatment centers are increasing.
This is the main counterweight: the company is still far from profitable, which limits near-term upside.

Viking Therapeutics Inc (VKTX)

Q3 20266 Jul – 24 Sep 2026

▲2▼1

Viking's VK2735 shines, but cash burn and dilution weigh

VK2735 efficacy and dosing VK2735 showed 22% weight loss and up to 97% maintained on less-frequent dosing, strong efficacy plus convenience that positions it against Lilly and Novo.
This is the key new clinical data that drove optimism in the quarter.
Takeover speculation Vertex's $10B Crinetics deal fueled takeover speculation, and an unsettled oral GLP-1 market keeps Viking's pipeline valuable.
This new external event increased investor interest in Viking as a potential acquisition target.
Widening losses and dilution Q2 net loss widened to $128.1M as R&D surged, and an upsized $500M stock and convertible note offering raises dilution concerns.
These new financial developments create a real counterweight to the positive pipeline news.
Long wait and valuation divide Phase 3 data remain years away, and analyst valuations diverge wildly ($92.72 vs. $14.02). Cash burn and funding needs will likely overhang the stock until VK2735 reaches market.
This highlights the ongoing uncertainty and long timeline that keep the stock volatile.

August 20266 Aug – 24 Sep 2026

▲2▼1

Viking's VK2735 data wows, but $500M raise dilutes

VK2735 maintenance data: 22% weight loss, up to 97% kept on less-frequent dosing Viking reported that its obesity drug VK2735 produced 22% weight loss and patients kept up to 97% of it when switched to every-other-week shots (90% monthly), versus 61% on placebo. This is the big driver: strong efficacy plus a more convenient schedule makes the drug a real contender against Lilly and Novo, lifting hopes for future sales and partnership or buyout interest.
This is the single biggest new event moving VKTX, directly boosting its competitive position and long-term value.
Upsized $500M stock and convertible note offering raises dilution worries Viking priced an upsized raise: 7.85 million shares at $35 plus $225 million of convertible notes, up from $200 million each. The cash funds VK2735 and VK3019 trials, but selling new shares dilutes existing owners and the convertible notes could dilute later. This is the main counterweight to the good data.
It is the key new financing event that pressures the stock by diluting current shareholders.
Big pharma GLP-1 race leaves room for Viking Lilly's Mounjaro and Zepbound sales surged while Novo's Ozempic and Wegovy stalled, and Lilly's oral pill Foundayo is just starting. Viking's oral VK2735 phase 3 is planned for late 2026. A fast-growing market with an unsettled oral segment keeps Viking's pipeline valuable, supporting the stock.
It shows the competitive landscape that makes Viking's oral and injectable programs strategically valuable.
Cash burn and capital needs remain the overhang Viking used about $96 million last quarter and cash fell to $502 million from $706 million. Management says cash lasts into 2028, but the new raise confirms trials are expensive. Until VK2735 reaches market, funding needs and dilution risk will keep weighing on the stock even as data improves.
It explains the persistent financial pressure that offsets clinical optimism for VKTX.

Latest6 Aug – 24 Sep 2026

▲2▼1

Viking's VK2735 data wows, but $500M raise dilutes

VK2735 maintenance data: 22% weight loss, up to 97% kept on less-frequent dosing Viking reported that its obesity drug VK2735 produced 22% weight loss and patients kept up to 97% of it when switched to every-other-week shots (90% monthly), versus 61% on placebo. This is the big driver: strong efficacy plus a more convenient schedule makes the drug a real contender against Lilly and Novo, lifting hopes for future sales and partnership or buyout interest.
This is the single biggest new event moving VKTX, directly boosting its competitive position and long-term value.
Upsized $500M stock and convertible note offering raises dilution worries Viking priced an upsized raise: 7.85 million shares at $35 plus $225 million of convertible notes, up from $200 million each. The cash funds VK2735 and VK3019 trials, but selling new shares dilutes existing owners and the convertible notes could dilute later. This is the main counterweight to the good data.
It is the key new financing event that pressures the stock by diluting current shareholders.
Big pharma GLP-1 race leaves room for Viking Lilly's Mounjaro and Zepbound sales surged while Novo's Ozempic and Wegovy stalled, and Lilly's oral pill Foundayo is just starting. Viking's oral VK2735 phase 3 is planned for late 2026. A fast-growing market with an unsettled oral segment keeps Viking's pipeline valuable, supporting the stock.
It shows the competitive landscape that makes Viking's oral and injectable programs strategically valuable.
Cash burn and capital needs remain the overhang Viking used about $96 million last quarter and cash fell to $502 million from $706 million. Management says cash lasts into 2028, but the new raise confirms trials are expensive. Until VK2735 reaches market, funding needs and dilution risk will keep weighing on the stock even as data improves.
It explains the persistent financial pressure that offsets clinical optimism for VKTX.

July 20266 Jul – 30 Jul 2026

▲2▼1

Viking's Obesity Pipeline Advances, But Cash Burn and Valuation Risks Loom

VK2735 Phase 2 Shows Rapid Weight Loss, Phase 3 Data Years Away VK2735 delivered mid-teens percentage weight loss in 13 weeks, faster than oral rivals. Phase 3 results are due mid-to-late 2027, with oral data in 2028-2029. This keeps the potential $100 billion market in play, supporting Viking's valuation, but the long timeline means no near-term revenue.
This is the core clinical update that drives Viking's long-term value and investor optimism.
Vertex's $10B Crinetics Deal Fuels Takeover Speculation for Viking Vertex's acquisition of Crinetics for $10 billion has reignited M&A interest in obesity drugmakers. Viking, with its late-stage VK2735 and early VK3019, is seen as a prime target. A buyout could offer a premium, but any deal depends on upcoming data and remains speculative.
M&A speculation can significantly boost Viking's stock price by implying a potential buyout premium.
Q2 2026 Net Loss Widens to $128.1 Million as R&D Spending Surges Viking reported a $128.1 million net loss, more than double last year's, with R&D expenses up to $115.8 million. Cash fell to $502 million from $706 million. This rising cash burn increases the risk of future dilution or financing, pressuring the stock.
The widening loss and shrinking cash highlight the financial strain of funding late-stage trials, a key risk for a pre-revenue company.
Analyst Valuation Gap: 120% Undervalued vs. DCF Overvalued One analyst narrative sees Viking 120% undervalued at $92.72 per share, while a DCF model suggests it's overvalued at $14.02. This huge discrepancy reflects uncertainty over pipeline success and funding needs, making the stock volatile and hard to value.
The stark valuation divide shows the market's uncertainty about Viking's prospects, which can cause sharp price swings.

6 Jul – 30 Jul 2026

▲2▼1

Viking's Obesity Pipeline Advances, But Cash Burn and Valuation Risks Loom

VK2735 Phase 2 Shows Rapid Weight Loss, Phase 3 Data Years Away VK2735 delivered mid-teens percentage weight loss in 13 weeks, faster than oral rivals. Phase 3 results are due mid-to-late 2027, with oral data in 2028-2029. This keeps the potential $100 billion market in play, supporting Viking's valuation, but the long timeline means no near-term revenue.
This is the core clinical update that drives Viking's long-term value and investor optimism.
Vertex's $10B Crinetics Deal Fuels Takeover Speculation for Viking Vertex's acquisition of Crinetics for $10 billion has reignited M&A interest in obesity drugmakers. Viking, with its late-stage VK2735 and early VK3019, is seen as a prime target. A buyout could offer a premium, but any deal depends on upcoming data and remains speculative.
M&A speculation can significantly boost Viking's stock price by implying a potential buyout premium.
Q2 2026 Net Loss Widens to $128.1 Million as R&D Spending Surges Viking reported a $128.1 million net loss, more than double last year's, with R&D expenses up to $115.8 million. Cash fell to $502 million from $706 million. This rising cash burn increases the risk of future dilution or financing, pressuring the stock.
The widening loss and shrinking cash highlight the financial strain of funding late-stage trials, a key risk for a pre-revenue company.
Analyst Valuation Gap: 120% Undervalued vs. DCF Overvalued One analyst narrative sees Viking 120% undervalued at $92.72 per share, while a DCF model suggests it's overvalued at $14.02. This huge discrepancy reflects uncertainty over pipeline success and funding needs, making the stock volatile and hard to value.
The stark valuation divide shows the market's uncertainty about Viking's prospects, which can cause sharp price swings.

Q2 202623 Jun – 3 Jul 2026

▲4

Viking's Obesity Pipeline Advances as Medicare Coverage Boosts Sector

Medicare GLP-1 Bridge coverage begins Starting July 1, 2026, Medicare's GLP-1 Bridge program covers anti-obesity drugs like Wegovy and Zepbound. This expands the market for weight-loss treatments, boosting demand expectations for Viking's VK2735 if approved. The news helped extend Viking's stock winning streak to eight days.
New Medicare coverage directly expands the addressable market for Viking's obesity drug, a key demand driver.
VK3019 enters first human trial Viking started a Phase 1 trial of VK3019, a new class of weight-loss drug using a different mechanism than GLP-1s. This expands the pipeline beyond VK2735, potentially offering another growth driver. However, it adds development costs for a pre-revenue company.
New clinical milestone for a second obesity candidate diversifies Viking's pipeline and future revenue potential.
VK2735 Phase 3 data expected 2027 Viking's lead obesity drug VK2735 is in Phase 3 trials, with top-line data expected no earlier than 2027. Phase 2 results showed up to 14.7% weight loss, competitive but behind rivals like Eli Lilly's retatrutide (28.3%). Success could unlock a $100 billion market.
The timing and potential of VK2735's Phase 3 data are central to Viking's valuation and investor expectations.
Stock gained 19.2% in June on pipeline optimism Viking shares rose 19.2% in June as investors grew optimistic about the weight-loss pipeline. The rally was fueled by Phase 2 results, pipeline advancements, and sector tailwinds. However, the stock remains volatile and high-risk, with no approved products yet.
Summarizes the period's strong stock performance and the underlying drivers, giving a big-picture view.

June 202623 Jun – 3 Jul 2026

▲4

Viking's Obesity Pipeline Advances as Medicare Coverage Boosts Sector

Medicare GLP-1 Bridge coverage begins Starting July 1, 2026, Medicare's GLP-1 Bridge program covers anti-obesity drugs like Wegovy and Zepbound. This expands the market for weight-loss treatments, boosting demand expectations for Viking's VK2735 if approved. The news helped extend Viking's stock winning streak to eight days.
New Medicare coverage directly expands the addressable market for Viking's obesity drug, a key demand driver.
VK3019 enters first human trial Viking started a Phase 1 trial of VK3019, a new class of weight-loss drug using a different mechanism than GLP-1s. This expands the pipeline beyond VK2735, potentially offering another growth driver. However, it adds development costs for a pre-revenue company.
New clinical milestone for a second obesity candidate diversifies Viking's pipeline and future revenue potential.
VK2735 Phase 3 data expected 2027 Viking's lead obesity drug VK2735 is in Phase 3 trials, with top-line data expected no earlier than 2027. Phase 2 results showed up to 14.7% weight loss, competitive but behind rivals like Eli Lilly's retatrutide (28.3%). Success could unlock a $100 billion market.
The timing and potential of VK2735's Phase 3 data are central to Viking's valuation and investor expectations.
Stock gained 19.2% in June on pipeline optimism Viking shares rose 19.2% in June as investors grew optimistic about the weight-loss pipeline. The rally was fueled by Phase 2 results, pipeline advancements, and sector tailwinds. However, the stock remains volatile and high-risk, with no approved products yet.
Summarizes the period's strong stock performance and the underlying drivers, giving a big-picture view.

23 Jun – 3 Jul 2026

▲4

Viking's Obesity Pipeline Advances as Medicare Coverage Boosts Sector

Medicare GLP-1 Bridge coverage begins Starting July 1, 2026, Medicare's GLP-1 Bridge program covers anti-obesity drugs like Wegovy and Zepbound. This expands the market for weight-loss treatments, boosting demand expectations for Viking's VK2735 if approved. The news helped extend Viking's stock winning streak to eight days.
New Medicare coverage directly expands the addressable market for Viking's obesity drug, a key demand driver.
VK3019 enters first human trial Viking started a Phase 1 trial of VK3019, a new class of weight-loss drug using a different mechanism than GLP-1s. This expands the pipeline beyond VK2735, potentially offering another growth driver. However, it adds development costs for a pre-revenue company.
New clinical milestone for a second obesity candidate diversifies Viking's pipeline and future revenue potential.
VK2735 Phase 3 data expected 2027 Viking's lead obesity drug VK2735 is in Phase 3 trials, with top-line data expected no earlier than 2027. Phase 2 results showed up to 14.7% weight loss, competitive but behind rivals like Eli Lilly's retatrutide (28.3%). Success could unlock a $100 billion market.
The timing and potential of VK2735's Phase 3 data are central to Viking's valuation and investor expectations.
Stock gained 19.2% in June on pipeline optimism Viking shares rose 19.2% in June as investors grew optimistic about the weight-loss pipeline. The rally was fueled by Phase 2 results, pipeline advancements, and sector tailwinds. However, the stock remains volatile and high-risk, with no approved products yet.
Summarizes the period's strong stock performance and the underlying drivers, giving a big-picture view.